Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

LANTHEUS HOLDINGS, INC.

(LNTH)
  Report
Delayed Nasdaq  -  04:00 2022-09-27 pm EDT
67.39 USD   +1.19%
09/13Lantheus, GE Healthcare Say Study Shows 18F flurpiridaz PET Radiotracer Can Improve Coronary Artery Disease Detection
MT
09/13GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
GL
09/13GE Healthcare and Lantheus Phase III Clinical Trial Finds flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Logo Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is an integrated provider of imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to Find, Fight and Follow serious medical conditions. The Company classify its commercial products in three categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other revenue. Its products in its precision diagnostics category includes DEFINITY, TechneLite, NEUROLITE, Xenon-133, Cardiolite, Gallium-67 and Thallium-201. Its products in its radiopharmaceutical oncology category includes PYLARIFY and AZEDRA. Its products in its strategic partnerships and other revenue product category includes RELISTOR, Automated Bone Scan Index (aBSI) and PYLARIFY AI. In addition to its commercial products and strategic partnerships with third parties, it also has ongoing clinical development programs, such as 1095 and LMI 1195. Its products are sold in both the United States and internationally.

Number of employees : 612 people.
Sales per Business
2021
DEFINITY232.7654.7%
TechneLite91.2921.5%
PYLARIFY43.4110.2%
Other Precision Diagnostics26.976.3%
Strategic Partnerships and Other25.305.9%
Other Radiopharmaceutical Oncology5.471.3%
USD in Million
Sales per region
20202021Delta
United States294.8086.9%382.6990% +29.81%
International44.6113.1%42.5210% -4.69%
USD in Million
Managers
Name Title Age Since
Mary Anne Heino Chief Commercial Officer 61 2013
Robert Marshall Chief Financial Officer & Treasurer 54 2021
Simon Robinson Senior VP-Research & Pharmaceutical Development 61 2018
Bela Denes Vice President-Medical Affairs - 2021
Iryna Teslenko Vice President-Clinical Development - 2021
Jean-Claude Provost Chief Medical Officer - 2022
Paul Blanchfield Chief Operating Officer 41 2022
Mark Kinarney Senior Director-Investor Relations - -
Daniel M. Niedzwiecki Secretary, Senior Vice President & General Counsel 44 2021
Etienne Montagut Senior Vice President-Corporate Development 46 2018
Members of the board
Name Title Age Since
Brian A. Markison Director 61 2012
Sam R. Leno Independent Director 75 2012
Julie Harris McHugh Independent Director 56 -
Gary John Pruden Independent Director 61 2018
James H. Thrall, Dr. Independent Director 77 -
Gérard Ber, Dr. Independent Director 63 2020
Heinz Christoph Mäusli Independent Director 58 2020
Mary Anne Heino Chief Commercial Officer 61 2013
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 68,741,886 67,061,221 97.6% 0 0.0% 97.6%
Shareholders
NameEquities%
The Vanguard Group, Inc. 7,270,243 10.6%
Investment Counselors of Maryland LLC 2,779,298 4.04%
Armistice Capital LLC 2,700,000 3.93%
SSgA Funds Management, Inc. 2,393,559 3.48%
T. Rowe Price Associates, Inc. (Investment Management) 2,316,891 3.37%
Farallon Capital Management LLC 2,250,000 3.27%
1832 Asset Management LP 1,885,400 2.74%
Scopia Capital Management LP 1,824,344 2.65%
Millennium Management LLC 1,822,426 2.65%
BlackRock Fund Advisors 1,744,659 2.54%
Company contact information
Lantheus Holdings, Inc.
331 Treble Cove Road
North Billerica, MA 01862

Phone : +1.978.671.8001
Web : http://www.lantheus.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Lantheus Holdings, Inc.